Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

EMD SERONO RESEARCH & DEVELOPMENT INSTITUTE, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

Phase 1

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: M9140
Drug: 5-fluorouracil (5-FU)
Drug: Bevacizumab
Drug: Capecitabine
Drug: Folinic acid

First Posted Date: 2022-07-19

Last Posted Date: 2025-05-07

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 200

Registration Number: NCT05464030

Locations: 🇺🇸
California Cancer Associates for Research & Excellence, Inc., Fresno, California, United States
🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States
🇺🇸
Mary Crowley Cancer Research, Dallas, Texas, United States

and more 31 locations

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Phase 1

Recruiting

Conditions: Metastatic or Locally Advanced Unresectable Solid Tumors

Interventions: Drug: Tuvusertib
Drug: Lartesertib
Drug: Avelumab

First Posted Date: 2022-05-31

Last Posted Date: 2025-07-04

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 123

Registration Number: NCT05396833

Locations: 🇺🇸
Providence Medical Foundation, Santa Rosa, California, United States
🇺🇸
University of Miami School of Medicine, Miami, Florida, United States
🇺🇸
Augusta University - formerly Georgia Regents University, Augusta, Georgia, United States

and more 17 locations

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Phase 3

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: Xevinapant
Radiation: IMRT
Drug: Placebo

First Posted Date: 2022-05-23

Last Posted Date: 2025-06-13

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 166

Registration Number: NCT05386550

Locations: 🇺🇸
University of Alabama at Birmingham - Dept of Radiation Oncology, Birmingham, Alabama, United States
🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
UC Health, Aurora, Colorado, United States

and more 203 locations

Met Non Small Cell Cancer Registry (MOMENT)

Recruiting

Conditions: Cancer

First Posted Date: 2022-05-17

Last Posted Date: 2025-06-19

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 700

Registration Number: NCT05376891

Locations: 🇺🇸
Holy Cross Health, Fort Lauderdale, Florida, United States
🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 61 locations

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Phase 2

Active, not recruiting

Conditions: Locally Advanced or Metastatic Urothelial Carcinoma

Interventions: Drug: Avelumab
Drug: NKTR-255
Drug: Sacituzumab Govitecan
Drug: M6223

First Posted Date: 2022-04-14

Last Posted Date: 2025-05-07

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 256

Registration Number: NCT05327530

Locations: 🇺🇸
Beacon Cancer Care, Coeur d'Alene, Idaho, United States
🇺🇸
University of Kansas Medical Center Research Institute, Inc. - 3901 Rainbow (MAIN), Kansas City, Kansas, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 92 locations

First in Human Study of M1069 in Advanced Solid Tumors

Phase 1

Terminated

Conditions: Metastatic or Locally Advanced Unresectable Solid Tumors

Interventions: Drug: M1069

First Posted Date: 2022-01-20

Last Posted Date: 2024-11-25

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 15

Registration Number: NCT05198349

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium), Nashville, Tennessee, United States
🇨🇦
Princess Margaret Cancer Centre, Toronto, Canada

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

Phase 2

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Enpatoran medium dose
Drug: Enpatoran high dose
Drug: Enpatoran low dose
Drug: Placebo

First Posted Date: 2021-12-17

Last Posted Date: 2024-12-05

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 456

Registration Number: NCT05162586

Locations: 🇺🇸
The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸
Bay Area Arthritis and Osteoporosis, Brandon, Florida, United States
🇺🇸
Charisma Medical and Research Center, Miami Lakes, Florida, United States

and more 150 locations

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Phase 1

Active, not recruiting

Conditions: Central Nervous System Tumors

Interventions: Drug: Avelumab
Drug: Lenvatinib

First Posted Date: 2021-10-18

Last Posted Date: 2025-04-15

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 17

Registration Number: NCT05081180

Locations: 🇨🇦
CHU Sainte-Justine, Montréal, Canada
🇨🇦
The Hospital for Sick Children, Toronto, Canada
🇫🇷
CHU Angers - Hôpital Hôtel Dieu - Service de Cancérologie Pédiatrique, Angers Cedex 9, France

and more 6 locations

Bintrafusp Alfa Program Rollover Study

Phase 3

Completed

Conditions: Lung Cancer
Cancer

Interventions: Drug: Bintrafusp alfa

First Posted Date: 2021-09-30

Last Posted Date: 2025-06-04

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 32

Registration Number: NCT05061823

Locations: 🇺🇸
The Center for Cancer and Blood Disorders a Division of American Oncology Partners of Maryland, P.A., Bethesda, Maryland, United States
🇺🇸
NIH National Institutes of Health/GMB LTIB, Bethesda, Maryland, United States
🇧🇪
Centre Hospitalier de l'Ardenne - PARENT, Libramont, Belgium

and more 18 locations

Next-Gen MS: Feed-forward PRO Data for MS Research

Terminated

Conditions: Multiple Sclerosis (MS)

First Posted Date: 2021-05-28

Last Posted Date: 2024-06-06

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 1594

Registration Number: NCT04907305

Locations: 🇺🇸
Alabama Neurology Associates, Birmingham, Alabama, United States
🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸
Atlanta Neuroscience Institute, Atlanta, Georgia, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy